Unknown

Dataset Information

0

Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?

ABSTRACT:

SUBMITTER: Patel DM 

PROVIDER: S-EPMC7792649 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?

Patel Dipal M DM   Dahl Neera K NK  

Clinical journal of the American Society of Nephrology : CJASN 20201229 1

Similar Datasets

Unknown Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD.
| S-EPMC8820994 | biostudies-literature
Unknown Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD.
| S-EPMC9091612 | biostudies-literature
Unknown The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD.
| S-EPMC12451683 | biostudies-literature
Unknown A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials.
| S-EPMC11405464 | biostudies-literature
Unknown Initial eGFR Changes Predict Response to Tolvaptan in ADPKD.
| S-EPMC11093546 | biostudies-literature
Unknown Tolvaptan in ADPKD Patients With Very Low Kidney Function.
| S-EPMC8343715 | biostudies-literature
Unknown Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
| S-EPMC7787121 | biostudies-literature
Unknown Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
| S-EPMC7792652 | biostudies-literature
Unknown Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial.
| S-EPMC5661830 | biostudies-literature
Unknown Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
| S-EPMC6480528 | biostudies-literature